Galderma blocks Dr. Reddy's IPRs
Washington DC | 17 February 2016

Galderma Laboratories has successfully blocked three inter partes review (IPR) petitions brought by generic manufacturer Dr. Reddy’s Laboratories.

Dr. Reddy’s sought to invalidate the claims of Galderma’s patent, covering its rosacea treatment Oracea (doxycycline), with three IPRs filed at the US Patent Trial and Appeal Board (PTAB) in August 2015.

In its petitions, Dr. Reddy’s claimed that prior art deems four of Galderma’s patent claims invalid.

The IPRs follow Galderma challenging Dr. Reddy’s Abbreviated New Drug Application for a generic version of the Oracea. Galderma sued Dr. Reddy’s for patent infringement in district court.

Stephen Maebius, partner from Foley & Lardner, which represented Galderma, said: “This represents a second attempt to invalidate a patent through the IPR process pertaining to the Oracea product.

“Following our successful defence of the first IPR attack, we are very pleased that the board denied institution of all three petitions filed against the new Oracea patent in this second wave.”

Author: Tammy Facey

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization